One Powerful Vision
For over 30 years, Ellex has been at the forefront of ophthalmic laser research and development. During this time, we have evolved from a small scientific laser company to a pioneer in the development of ophthalmic diagnostic and treatment technologies. Today, we are as passionate about ophthalmic laser technology, and its power to heal, as the day we set out on this magnificent journey.
The evolution of Ellex begins when Quentron Electronics, an Australian-based scientific laser company, is awarded a grant by the Australian government to develop its laser technology for use in ophthalmology.
Ellex launches is first ophthalmic laser product, the Laserex LQ1106 YAG photodisruptor, for the treatment of secondary cataracts.
Ellex spins off the laser technology from Quentron as a result of a management buyout, and begins operating as an independent company.
Ellex enters into an Original Equipment Manufacturer (OEM) agreement with Alcon (Alcon Laboratories Ltd.) to develop and supply the Alcon 3000LE laser system based on the Laserex photodisruptor platform. More than 2,000 of these 3000LE systems were delivered to market under this agreement, which ended in 2012.
Ellex establishes a direct sales and service subsidiary in Minneapolis, USA.
Ellex launches the original Super Q® YAG laser, which has since become the industry’s most popular photodisruptor.
Ellex enters into an OEM agreement with Coherent (now Lumenis) to develop and supply the Aura photodisruptor based on the Laserex photodisruptor platform. More than 900 of these systems were delivered to market under this agreement, which ended in 2004.
Ellex enters the photocoagulator market with the launch of the Integre®, a solid-state, green photocoagulator. The Integre® is the first and only green laser photocoagulator to integrate the laser cavity into the slit lamp delivery system.
Ellex IPO on the Australian Stock Exchange.
Ellex enters into a second OEM agreement with Coherent (now Lumenis) to develop and supply the Selecta Duet™ SLT laser system for the treatment of glaucoma. More than 500 of these systems were delivered to market under this agreement, which ended in March 2006.
Ellex establishes a direct sales and service subsidiary in Japan, with offices in Tokyo and Osaka.
Ellex transitions its business from OEM supply to direct sales and marketing of its own branded products under the Ellex name. Today, more than 95 percent of Ellex sales are direct.
Ellex enters the selective laser trabeculoplasty (SLT) market for the treatment of glaucoma with the launch of the Tango™ SLT/YAG combination laser. Today, more than 2,500 Ellex-manufactured SLT laser systems are in use worldwide.
Ellex establishes a direct sales subsidiary in Australia.
Ellex establishes a sales and service operation in France to strengthen support for the Company’s European distribution network.
Ellex enters the multi-color photocoagulator market with the launch of the Integre Duo™, the world’s first solid-state laser photocoagulator to deliver clinically proven red and green wavelengths.
Ellex expands its product portfolio to include diagnostic ultrasound through the acquisition of California-based ultrasound pioneers Innovative Imaging, Inc.
Ellex launches a preliminary clinical trial program for Ellex Retinal Rejuvenation Therapy (Ellex 2RT™) – a breakthrough laser therapy for the treatment of retinal disease.
Ellex establishes a direct sales and service subsidiary in Germany.
Ellex announces positive interim clinical trial results for Ellex 2RT™ in the treatment of early Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME) – two of the leading causes of blindness in the developed world.
Ellex launches Integre Yellow™, the first and only high-power, integrated yellow photocoagulator. Ellex launches the New Generation Eye Cubed™ diagnostic ultrasound system.
Ellex consolidates laser and ultrasound manufacturing out of its state-of-the art production facility in Adelaide, Australia.
Ellex launches Ultra Q Reflex™, a multi-modality YAG laser that enables ophthalmologists to perform laser vitreolysis in the treatment of floaters, in addition to performing capsolutomy and iridotomy YAG laser procedures.
In partnership with the Centre for Eye Research Australia (CERA), Ellex launches a multi-centre clinical trial program to validate the clinical efficacy of Retinal Rejuvenation Therapy (2RT™) in the treatment of early Age-Related Macular Degeneration (AMD).
Ellex launches its proprietary selective laser trabeculoplasty (SLT) technology for the treatment of glaucoma in the United States.
Ellex expands glaucoma product offering through acquisition of the Canaloplasty technology platform from US-based iScience Interventonal, Inc . Canaloplasty is a restorative surgical procedure, which uses patented microcatheter technology to restore the eye’s natural outflow pathways in the treatment of glaucoma.
Ellex partners with clinicians in the USA and Europe to pioneer ABiC, a minimally invasive glaucoma surgery (MIGS) for the treatment of glaucoma.
Ellex relocates corporate headquarters to purpose-built facility in Mawson Lakes, Adelaide, to accommodate ongoing growth in its manufacture of devices to treat glaucoma, diabetic eye disease, secondary cataract, age-related macular degeneration (AMD) and vitreous opacities.